Plant Name: Ampelopsis brevipedunculata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CTDSP1; TDP1; PIK3CA; PIK3CB; PKM; HSD17B1; AKR1B1; HSD17B2; GFER; NQO2; NOX4; ALOX15; USP2; | |
| DAPK1; FLT3; | |
| CA2; CA1; CA12; CA9; CA13; CA14; CA4; CA3; CA5B; CA5A; CA6; CA7; | |
| AR; | |
| ESR1; | |
| ESRRA; | |
| ALOX5; TYR; MAOA; PTGS2; PTGS1; XDH; | |
| AHR; HIF1A; TP53; | |
| ABCG2; ABCC1; | |
| SLC6A2; | |
| HTT; LMNA; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.449E-11 | 2.540E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.617E-11 | 2.590E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.459E-11 | 3.884E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4, PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.511E-10 | 1.175E-07 | AR, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESRRA, NQO2, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.308E-10 | 2.183E-07 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.439E-10 | 4.124E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.068E-09 | 1.154E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.100E-08 | 9.942E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.923E-08 | 3.015E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.678E-07 | 1.296E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 1.740E-06 | 5.192E-04 | ALOX15, APP, CA2, CYP1A1, CYP1A2, HIF1A, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 2.669E-06 | 7.647E-04 | ALOX15, ALOX5, PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.110E-06 | 8.682E-04 | AR, CYP3A4, ESR1, ESRRA, HSD17B1 |
| BP | GO:0050896; response to stimulus | GO:1901701; cellular response to oxygen-containing compound | 3.448E-06 | 9.386E-04 | AKR1B1, APP, AR, CYP1B1, DAPK1, ESR1, NOX4, PIK3CA, PKM, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.537E-06 | 9.508E-04 | APP, AR, CYP1A1, CYP1B1, ESR1, FLT3, NOX4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.751E-06 | 9.962E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.280E-29 | 2.787E-25 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 5.801E-06 | 1.373E-03 | ABCG2, APP, CA12, CA2, CA7, ESR1, HIF1A, HTT, PIK3CB, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 6.835E-06 | 1.567E-03 | PTGS1, PTGS2 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 8.365E-06 | 1.803E-03 | AHR, AR, ESR1, ESRRA |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 9.478E-06 | 1.976E-03 | ALOX15, ALOX5, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 9.529E-06 | 1.976E-03 | AKR1B1, CYP1A2, NOX4, NQO2, XDH |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 1.538E-05 | 3.044E-03 | ABCG2, APP, CA2, CA7, ESR1, HIF1A, HTT, PIK3CB, TP53 |
| BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 2.013E-05 | 3.746E-03 | AKR1B1, CYP3A4, HSD17B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.047E-05 | 3.746E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 2.047E-05 | 3.746E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.047E-05 | 3.746E-03 | CYP1A1, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.785E-05 | 5.012E-03 | CA2, CA7, HIF1A, HTT, PIK3CB, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.959E-05 | 5.281E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0008210; estrogen metabolic process | 3.375E-05 | 5.926E-03 | CYP1B1, HSD17B1, HSD17B2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.087E-05 | 6.903E-03 | CYP1A1, CYP1A2 |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 4.090E-05 | 6.903E-03 | APP, NOX4, PTGS2, TP53, TYR |
| MF | GO:0005488; binding | GO:0050660; flavin adenine dinucleotide binding | 4.327E-05 | 7.138E-03 | GFER, NOX4, NQO2, XDH |
| BP | GO:0008152; metabolic process | GO:0072330; monocarboxylic acid biosynthetic process | 4.364E-05 | 7.145E-03 | ALOX15, CYP1A1, PKM, PTGS1, PTGS2 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 4.850E-05 | 7.709E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006636; unsaturated fatty acid biosynthetic process | 6.036E-05 | 9.192E-03 | ALOX15, PTGS1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 6.476E-05 | 9.793E-03 | CYP1A1, PTGS2, TP53, TYR |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.619E-22 | 6.118E-18 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.820E-21 | 4.257E-17 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.142E-28 | 1.611E-26 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.913E-10 | 2.758E-08 | CYP2C9; APP; MAOA; ALOX5; ALOX15; CYP2C19; PTGS2; PTGS1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.960E-09 | 1.043E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.501E-09 | 7.056E-08 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.119E-08 | 2.253E-07 | CYP2C9; ALOX5; ALOX15; CYP2C19; PTGS2; PTGS1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.890E-08 | 6.094E-07 | MAOA; ALOX15; AKR1B1; PTGS2; CYP2C19; CYP3A4; TYR; PTGS1; CYP2C9; PKM; HSD17B1; ALOX5; HSD17B2; CYP1A2; CYP1A1; XDH |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.423E-09 | 2.093E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.799E-08 | 3.170E-07 | PKM; PIK3CA; FLT3; PIK3CB; TP53; HIF1A |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.995E-09 | 2.253E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 8.761E-07 | 1.235E-05 | CYP2C9; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.781E-06 | 7.355E-05 | AR; PIK3CA; FLT3; DAPK1; PIK3CB; PTGS2; HIF1A; TP53 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.162E-06 | 1.489E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.202E-06 | 3.763E-05 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.242E-05 | 1.174E-04 | PIK3CA; PIK3CB; TP53; ESR1; HIF1A |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.249E-05 | 1.174E-04 | PIK3CA; PIK3CB; PTGS2; PTGS1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.264E-05 | 1.995E-04 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 7.804E-05 | 5.791E-04 | AR; PIK3CA; PIK3CB; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.649E-04 | 1.162E-03 | PIK3CA; PIK3CB; TP53; HIF1A; ESR1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 6.825E-05 | 5.347E-04 | PIK3CA; PIK3CB; PTGS2; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.477E-04 | 1.597E-03 | ABCC1; PIK3CA; PIK3CB; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.453E-04 | 2.415E-03 | PIK3CA; LMNA; PIK3CB; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.937E-04 | 2.313E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.161E-04 | 1.938E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.148E-04 | 2.339E-03 | PIK3CA; FLT3; PIK3CB |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.492E-04 | 1.597E-03 | PKM; PIK3CA; PIK3CB |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.825E-04 | 2.520E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.065E-04 | 2.551E-03 | PIK3CA; PIK3CB; PTGS2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 6.104E-04 | 2.812E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 9.380E-04 | 3.575E-03 | ABCC1; PIK3CA; CYP1B1; PTGS2; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 5.313E-04 | 2.583E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.383E-04 | 2.812E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.838E-03 | 6.479E-03 | PKM; PIK3CA; PIK3CB; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 6.383E-04 | 2.812E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 7.901E-04 | 3.277E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 8.230E-04 | 3.316E-03 | PIK3CA; PIK3CB; ESR1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.567E-04 | 3.356E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.778E-03 | 6.429E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.062E-03 | 7.092E-03 | PIK3CA; PIK3CB; ESR1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.901E-04 | 3.277E-03 | CA2; CYP3A4; ABCG2 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.183E-03 | 7.330E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.783E-03 | 8.917E-03 | PIK3CA; PIK3CB; PTGS2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.309E-03 | 7.571E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.392E-03 | 1.063E-02 | PIK3CA; ALOX5; PIK3CB |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.557E-03 | 1.078E-02 | PIK3CA; PIK3CB; TP53 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 3.726E-03 | 1.094E-02 | PIK3CA; PIK3CB; PTGS1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.743E-03 | 1.338E-02 | PIK3CA; PIK3CB; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 5.047E-03 | 1.369E-02 | PIK3CA; PIK3CB; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 6.143E-03 | 1.547E-02 | PIK3CA; PIK3CB; TP53 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 7.634E-03 | 1.888E-02 | PIK3CA; PIK3CB; PTGS2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.482E-02 | 3.395E-02 | PIK3CA; PIK3CB; TP53 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.078E-02 | 4.577E-02 | PIK3CA; PIK3CB |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.305E-02 | 3.118E-02 | PIK3CA; PIK3CB |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.493E-02 | 3.395E-02 | PIK3CA; PIK3CB |
| hsa00562 | Inositol phosphate metabolism_Homo sapiens_hsa00562 | 1.416E-02 | 3.328E-02 | PIK3CA; PIK3CB |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.692E-02 | 3.787E-02 | PIK3CA; PIK3CB |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.162E-02 | 2.825E-02 | PIK3CA; PIK3CB |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.906E-03 | 1.356E-02 | DAPK1; TP53 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 4.448E-03 | 1.280E-02 | PIK3CA; PIK3CB |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 5.885E-03 | 1.537E-02 | PIK3CA; PIK3CB |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 6.142E-03 | 1.547E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 5.632E-03 | 1.498E-02 | ABCC1; ABCG2 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 3.595E-03 | 1.078E-02 | MAOA; TYR |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.559E-03 | 5.783E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 6.344E-05 | 5.262E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; PTGS2; PTGS1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ESR1; SLC6A2; PTGS2; PTGS2; PTGS2; PTGS2; PKM; PTGS1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; PTGS2 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; MAOA |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; PIK3CA |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2; MAOA; MAOA |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; SLC6A2; MAOA |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| C00-D49: Neoplasms | Melanoma | C43 | TYR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; HIF1A; TP53; PIK3CA; PIK3CB; CA1; FLT3; FLT3; CA9; ESR1; ESR1; PTGS2; NQO2; APP |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; AKR1B1; PTGS2; PTGS2; PTGS2; PTGS2; ESRRA |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3; CA9; ESR1; ESR1; NQO2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; PTGS2; APP |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1; PTGS1; ESRRA |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | SLC6A2; SLC6A2; SLC6A2; SLC6A2; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PTGS2; ABCC1; ABCC1 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; SLC6A2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; PIK3CB |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| NA: NA | HIV infections | NA | AHR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Edema | NA | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; PTGS2; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PTGS2; PTGS2; ABCC1; ESRRA |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; PIK3CA; PIK3CB; FLT3; CA9; PKM |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; PTGS1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; PTGS1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2; PTGS1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| NA: NA | Menopausal disorder | NA | ESR1 |